Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Friday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays decreased their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th.

Cellectis Stock Down 1.4 %

Shares of CLLS opened at $2.10 on Friday. Cellectis has a fifty-two week low of $1.70 and a fifty-two week high of $3.77. The firm has a market cap of $116.73 million, a PE ratio of -1.62 and a beta of 3.10. The company’s fifty day moving average is $1.95 and its two-hundred day moving average is $2.17. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same quarter last year, the business earned ($0.31) earnings per share. Analysts forecast that Cellectis will post -0.46 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Long Focus Capital Management LLC boosted its stake in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the period. First Affirmative Financial Network purchased a new position in Cellectis in the 3rd quarter worth about $45,000. Finally, XTX Topco Ltd acquired a new stake in Cellectis during the 2nd quarter worth about $29,000. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.